1. At a Glance – The “Doctor, Patient Is Stable… But Bills Are Wild” Edition
OneSource Specialty Pharma Ltd currently sits on a ₹16,413 crore market cap, trading at ₹1,432, down ~22% in 3 months and ~28% in 6 months, which tells you the market mood faster than any analyst note. On paper, this is a global biologics CDMO, born out of Strides Pharma’s demerger, blessed with EU-GMP + USFDA approved plants, and flexing a 27–28% operating margin in its better quarters.
But then reality walks in wearing Crocs.
Despite FY25 sales of ₹1,445 crore, TTM PAT is only ₹20 crore, ROCE is 5.52%, ROE is 3.34%, and interest coverage is an anxiety-inducing 1.01x. The stock trades at 537x earnings, not because profits are exploding, but because profits are microscopic relative to enterprise value.
Debt stands at ₹1,295 crore, promoter holding has slid to ~29.9%, and 18.5% promoter shares are pledged. Meanwhile, FIIs and DIIs are increasing exposure like they’re betting on “FY27 will fix everything”.
So what is this company?
A future biologics powerhouse?
Or a very expensive incubation centre funded by debt and hope?
Let’s open the audit file.
2. Introduction – Born From a Demerger, Raised on Capex, Judged by Cash Flow
OneSource Specialty Pharma Ltd didn’t grow organically like a typical mid-cap pharma. It was engineered.
In September 2023, Strides PharmaScience carved out its CDMO + Oral Softgel business, merged it with Steriscience’s injectables CDMO, parked it inside Stelis Biopharma, and then rebranded it in Feb 2024 as OneSource Specialty Pharma Ltd. Classic corporate move: separate the “future story” from the “legacy headache”.
The idea was simple:
- Strip out low-margin generics
- Build a pure-play CDMO + biologics platform
- Raise capital independently
- Get global clients
- Let valuation imagination do the rest
And to be fair, revenue did scale fast.
Sales jumped from ₹172 crore in FY24 to ₹1,445 crore in FY25. That’s not a typo.
But profits?
Still recovering from years of losses, heavy depreciation, interest costs, and biologics gestation timelines that move slower than regulatory approvals.
This is not a “quarterly momentum” stock.
This is a “believe for 5 years or suffer for 5 quarters” situation.
So let’s understand what exactly they do before we judge the balance sheet carnage.
3. Business Model – WTF Do They Even Do? (CDMO Edition)
OneSource is a Contract Development and Manufacturing Organisation (CDMO) focused on complex injectables, biologics, biosimilars,
